Balazs Halmos, MD, discussed the potential impact of subcutaneous amivantamab for patients with EGFR -mutated NSCLC. Halmos oversees the thoracic clinical trials program of novel clinical studies at ...
Atezolizumab Subcutaneous Data and Implementation Considerations. The subcutaneous formulation of atezolizumab (PD-L1 inhibitor) received approval approximately 1 year ago based o ...
The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback